Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma: A retrospective analysis

Strahlentherapie und Onkologie

Volumn 180, Issue 12, 2004, Pages 751-757

  Brunner, Thomas B ^a   Schwab, Dieter ^a   Meyer, Thomas ^a   Sauer, Rolf ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Chemoradiation; Cholangiocarcinoma; Stenting

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PREDICTION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; GERMANY; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; PREVALENCE; PROGNOSIS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STENTS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 11944256459     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-004-1315-1     Document Type: Article

References (34)

1. Alden ME, Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 1994;28:945-51.
2. Beyer-Enke SA, Seegenschmiedt MH, Keilholz L. New options in diagnosis and therapy of an unresectable hilar carcinoma. Tumordiagn Ther 1995; 16:125-7.
3. Bowling TE, Galbraith SM, Hatfield AR, et al. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 1996;39:852-5.
4. Brunner TB, Grabenbauer GG, Kastl S, et al. Preoperative chemoradiation in locally advanced pancreatic carcinoma: a phase II study. Onkologie 2000; 23:436-42.
5. Brunner TB, Grabenbauer GG, Klein P, et al. Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003;55:144-53.
6. Crane CH, Macdonald KO, Vauthey JN, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 2002;53:969-74.
7. De Groen PC, Gores GJ, LaRusso NF, et al. Biliary tract cancers. N Engl J Med 1999;341:1368-78.
8. Dunst J, Stadler P, Becker A, et al. Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol 2003;179:521-6.
9. Foo ML, Gunderson LL, Bender CE, et al. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 1997;39:929-35.
10. Gerhards MF, den Hartog D, Rauws EA, et al. Palliative treatment in patients with unresectable hilar cholangiocarcinoma: results of endoscopic drainage in patients with type III and IV hilar cholangiocarcinoma. Eur J Surg 2001;167:274-80.
11. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
12. Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 1998;34:977-86.
13. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234: 507-17.
14. Kim S, Kim SW, Bang YJ, et al. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2002;54:414-9.
15. Kopelson G, Galdabini J, Warshaw AL, et al. Patterns of failure after curative surgery for extra-hepatic biliary tract carcinoma: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1981;7:413-7.
16. Kouvaris J, Kouloulias V, Malas E, et al. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy. Strahlenther Onkol 2003;179:167-74.
17. Kurek R, Kalogera-Fountzila A, Muskalla K, et al. Usefulness of tumor volumetry as a prognostic factor of survival in head and neck cancer. Strahlenther Onkol 2003;179:292-7.
18. Lohr F, Dobler B, Mai S, et al. Optimization of dose distributions for adjuvant locoregional radiotherapy of gastric cancer by IMRT. Strahlenther Onkol 2003;179:557-63.
19. Mason KA, Milas L, Hunter NR, et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 1999; 44:1125-35.
20. Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999;59:107-14.
21. Minsky BD, Wesson MF, Armstrong JG, et al. Combined modality therapy of extrahepatic biliary system cancer. Int J Radiat Oncol Biol Phys 1990; 18:1157-63.
22. Morganti AG, Forni F, Macchia G, et al. Chemoradiation of unresectable pancreatic carcinoma: impact of pretreatment hemoglobin level on patterns of failure. Strahlenther Onkol 2003;179:87-92.
23. Morganti AG, Trodella L, Valentini V, et al. Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys 2000;46:913-9.
24. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-7.
25. Prat F, Chapat O, Ducot B, et al. Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. Gut 1998;42:76-80.
26. Schäfer U, Micke O, Müller SB, et al. Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol 2003;179:527-34.
27. Scheithauer W. Review of gemcitabine in biliary tract carcinoma. Semin Oncol 2002;29:40-5.
28. Schleicher UM, Staatz G, Alzen G, et al. Combined external beam and intraluminal radiotherapy for irresectable Klatskin tumors. Strahlenther Onkol 2002;178:682-7.
29. Serafini FM, Sachs D, Bloomston M, et al. Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg 2001;67:839-43.
30. Urego M, Flickinger JC, Carr BI. Radiotherapy and multimodality management of cholangiocarcinoma. Int J Radiat Oncol Biol Phys 1999;44:121-6.
31. Van Moorsel CJ, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999;80:981-90.
32. Warren KW, Hardy KJ, O'Rourke MG. Primary neoplasia of the gallbladder. Surg Gynecol Obstet 1968;126:1036-40.
33. Weiss C, Grabenbauer GG, Sauer R, et al. Significant increase in residual DNA damage as a possible mechanism of radiosensitization by gemcitabine. Strahlenther Onkol 2003;179:93-8.
34. Wilkowski R, Thoma M, Heinemann V, et al. Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer - feasible and effective. Strahlenther Onkol 2003;179:78-86.